|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||2.0800 - 2.0800|
|52 Week Range||1.7500 - 3.1800|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A consortium led by state-owned pharma giant Sinopharm plans to take private China Traditional Chinese Medicine Holdings in a deal that would value the firm at at least $3.3 billion, said two people with direct knowledge of the matter. Sinopharm, China TCM's parent and major shareholder, is teaming up with the next two biggest stockholders, Ping An Insurance Group Co of China and executive director Wang Xiaochun, said the people, with the three holding a combined 49.4% stake. It plans to offer at least HK$5.10 ($0.66) per share for China TCM, the people said, a premium of about 33% to the average share price over the past month of HK$3.83.
A volunteer in the local Peruvian trial of Sinopharm Group Co Ltd's coronavirus vaccine has died from COVID-19 related pneumonia, the university carrying out the trial said on Tuesday. Cayetano Heredia University, which is involved with the study, said that it did not know if the volunteer had received the vaccine or the placebo in the double blind trial. Peru is being hit by a second wave of COVID-19 infections.
China's Sinopharm Group and Pfizer Inc have requested approval for use of their COVID-19 vaccines in Peru as the Andean country grapples with a second wave of the coronavirus, a health official said on Tuesday. Carmen Ponce, general director of state drug regulator Digemid, said both drugmakers requested the registration last week after presenting "preliminary information" from their Phase III COVID-19 vaccine trials. Ponce added that authorization requests from other vaccine makers, such as AstraZeneca Plc and Russia's Gamaleya, are expected in the next few days.